Viska Bio
- Biotech or pharma, therapeutic R&D
Viska is developing VISK-103, a fusion protein of an EGFR targeting domain and xanthine oxidase. For glioblastoma, VISK-103's best-in-class MoA is built on inhibiting EGFR signalling, mediating a local bystander effect and global neoantigen vaccination.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}